| Description | TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease. |
| In vitro | In the time-course study,TDN-345 treatment with 10 μM significantly increases the intracellular NGF content. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM(ED50 of 0.88 μM)[1]. |
| In vivo | When administered orally twice TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score, 60 min before ischemia and 90 min after recirculation. Additionally, In SHRSP, TDN-345 decreases the mortality and recurrence of stroke [2]. |
| molecular weight | 468.58 |
| Molecular formula | C28H34F2N2O2 |
| CAS | 134069-68-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Fukumoto H, et al. The novel compound TDN-345 induces synthesis/secretion of nerve growth factor in C6-10A glioma cells. Brain Res. 1997 Nov 7;774(1-2):87-93. 2. Nakayama T, et al. Beneficial effects of TDN-345, a novel Ca2+ antagonist, on ischemic brain injury and cerebral glucose metabolism in experimental animal models with cerebrovascular lesions. Brain Res. 1997 Jul 11;762(1-2):203-10. |